From stable to advanced heart failure: contemporary treatment strategies based on the European Society of Cardiology Congress 2026

Marchenko D.P.

Main
Publications
From stable to advanced heart failure: contemporary treatment strategies based on the European Society of Cardiology Congress 2026

October 26, 2026

Marchenko D.P.

УДК: УДК 616.12-008.46

DOI: DOI: 10.32471/umj.1680-3051.281806

Keywords :

cardiogenic shock,

decompensated heart failure,

ESC Congress 2026,

foundational medical therapy,

heart failure,

heart transplantation,

mechanical circulatory support

Resume

This article summarizes contemporary strategies for the management of heart failure (HF) presented at the European Society of Cardiology Congress (ESC Congress 2026). Updated approaches to foundational and additional medical therapy, treatment individualization and optimization, as well as criteria for cardiac function improvement and recovery, are discussed. Particular attention is given to interventional therapies, telemonitoring, and natriuresis-guided diuretic treatment in patients with decompensated HF. The article also addresses the management of cardiogenic shock, criteria for advanced HF, mechanical circulatory support, and heart transplantation. The importance of early treatment optimization and individualized selection of therapeutic strategies is emphasized.

References

1. Køber L., Adamo M., Ruwald A.-C. et al. (2026) 2026 ESC Guidelines for the management of heart failure: Developed by the task force for the management of heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J., 47(38): 5346–5457. doi.org/10.1093/eurheartj/ehag100.
2. Jhund P.S., Talebi A., Henderson A.D. et al. (2024) Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet, 404(10458): 1119–1131. doi.org/10.1016/S0140-6736(24)01733-1.
3. Damman K., van Veldhuisen D.J., Bauersachs J. et al. (2026) Efficacy and safety of digitalis glycosides in heart failure: a meta-analysis. JAMA, 335(23): 2029–2037. doi.org/10.1001/jama.2026.7886.
4. Armstrong P.W., Pieske B., Anstrom K.J. et al. (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 382(20): 1883–1893. doi.org/10.1056/NEJMoa1915928.
5. Zannad F., O’Connor C.M., Butler J. et al. (2025) Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet, 406(10510): 1351–1362. doi.org/10.1016/S0140-6736(25)01682-4.
6. Hulot J.-S., ter Maaten J.M., Bayes-Genis A. et al. (2025) Heart failure improvement, remission, and recovery: a European Journal of Heart Failure expert consensus document. Eur. J. Heart Fail., 27(10): 1807–1819. doi.org/10.1002/ejhf.3732.
7. ter Maaten J.M., Beldhuis I.E., van der Meer P. et al. (2023) Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nat. Med., 29(10): 2625–2632. doi.org/10.1038/s41591-023-02532-z.
8. Dauw J., Charaya K., Lelonek M. et al. (2024) Protocolized natriuresis-guided decongestion improves diuretic response: the multicenter ENACT-HF study. Circ. Heart Fail., 17(1): e011105. doi.org/10.1161/CIRCHEARTFAILURE.123.011105.
9. Mullens W., Dauw J., Martens P. et al. (2022) Acetazolamide in acute decompensated heart failure with volume overload. N. Engl. J. Med., 387(13): 1185–1195. doi.org/10.1056/NEJMoa2203094.
10. Trullàs J.C., Morales-Rull J.L., Casado J. et al. (2023) Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur. Heart J., 44(5): 411–421. doi.org/10.1093/eurheartj/ehac689.
11. Berg D.D., Patel S.M., Haller P.M. et al. (2025) Dapagliflozin in patients hospitalized for heart failure: primary results of the DAPA ACT HF-TIMI 68 randomized clinical trial and meta-analysis of sodium-glucose cotransporter-2 inhibitors in patients hospitalized for heart failure. Circulation, 152(20): 1411–1422. doi.org/10.1161/CIRCULATIONAHA.125.076575.
12. Møller J.E., Engstrøm T., Jensen L.O. et al. (2024) Microaxial flow pump or standard care in infarct-related cardiogenic shock. N. Engl. J. Med., 390(15): 1382–1393. doi.org/10.1056/NEJMoa2312572.
13. Thiele H., Møller J.E., Henriques J.P.S. et al. (2024) Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up. Lancet, 404(10457): 1019–1028. doi.org/10.1016/S0140-6736(24)01448-X.
14. Mehra M.R., Goldstein D.J., Cleveland J.C. et al. (2022) Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA, 328(12): 1233–1242. doi.org/10.1001/jama.2022.16197.
15. Schmitto J.D., Shaw S., Garbade J. et al. (2024) Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry. Eur. Heart J., 45(8): 613–625. doi.org/10.1093/eurheartj/ehad658.
16. Pagnesi M., Lombardi C.M., Chiarito M. et al. (2022) Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry. Eur. J. Heart Fail., 24(9): 1493–1503. doi.org/10.1002/ejhf.2561.